4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-13-000078
$BHCCIK 0000885590operating
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 5:08 PM ET
Size
9.7 KB
Accession
0000885590-13-000078
Insider Transaction Report
Form 4
Weldon Ryan
EVP, Company Group Chairman
Transactions
- Exercise/Conversion
Common Stock, no par values
2013-09-03+19,000→ 84,928 total - Tax Payment
Common Stock, no par values
2013-09-03−9,859→ 75,069 total - Exercise/Conversion
Restricted Share Units
2013-09-03+19,000→ 19,000 totalExercise: $0.00→ Common Stock (19,000 underlying)
Footnotes (3)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported in Table II. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $55.66 starting on December 11, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 11, 2015, 50% on December 11, 2015 and 25% on March 11, 2016. Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. This is the first payout due to meeting the single vesting accelerated price.
- [F2]This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1.
- [F3]This number represents common shares withheld to satisfy certain tax withholding obligations due upon vesting of Performance Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Sep 2, 8:00 PM ET
- Accepted
- Sep 3, 5:08 PM ET
- Size
- 9.7 KB